Programmable insect cell carriers for systemic delivery of integrated cancer biotherapy
Dominic G. Roy(University of Ottawa), Harold Atkins(University of Ottawa), J. Andrea McCart(Toronto General Hospital), John C. Bell(Ottawa Hospital), Rebecca C. Auer(Ottawa Hospital), Christiano Tanese de Souza(Ottawa Hospital), Anthony Power(University of Ottawa), Marie‐Claude Bourgeois‐Daigneault(Centre Hospitalier de l’Université de Montréal), David F. Stojdl(Ottawa Regional Cancer Foundation), Lisa Ferreira(Discovery Centre), Brian D. Lichty(McMaster University Medical Centre), Theresa Falls(Ottawa Hospital), A. Stern(University of Maryland, College Park)
Cited by 15
Related Papers
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
|Cancer Cell|2003|850
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
|Nature Medicine|2000|816
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
|The Lancet Oncology|2008|522
A FLUORINATED GLUCOSE ANALOG, 2-FLUORO-2-DEOXY-D-GLUCOSE (F-18)
|Journal of Computer Assisted Tomography|1980|503
Glucose Metabolic Rate Kinetic Model Parameter Determination in Humans: The Lumped Constants and Rate Constants for [ <sup>18</sup> F]Fluorodeoxyglucose and [ <sup>11</sup> C]Deoxyglucose
|Journal of Cerebral Blood Flow & Metabolism|1985|419